Fig. 1 · Structure

Documents & Downloads

TCS 1102

Cat. No. A13439 CAS 916141-36-1

Dual orexin receptor antagonist

TCS 1102 is a potent, dual orexin receptor antagonist (Ki values are 0.2 and 3 nM for OX2 and OX1 receptors respectively).

In Stock

Publications for TCS 1102

1 publication citing this product

  1. Tung-Yen Lee, .et al. , Front Psychiatry, 2023, Jun 29;14:1196994 PMID: 37457782

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

TCS 1102 showed functional antagonism of human OX1 and OX2 orexin receptors in recombinant CHO cells. At 10 μM, it fully blocked the calcium response to 1 nM orexin-A in the reported assay. This experiment establishes response blockade under the tested conditions; it does not determine binding affinity or antagonist potency. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
OX1 Receptor Ki 3 nM
OX2 Receptor Ki 0.2 nM

TCS 1102 Research Summary

This section summarizes 1 in vitro study of TCS 1102 from 1 published reference.

TCS 1102 In Vitro Studies

In human OX1- or OX2-expressing CHO cells, calcium responses to Yan 7874 were only partly inhibited by 10 μM TCS 1102. Receptor-negative CHO controls also responded to Yan 7874, limiting attribution of its total calcium signal to orexin receptors. [1]

Calcium-response antagonism in human orexin receptor-expressing CHO cells

Cell-based study · CHO-K1 cells expressing human OX1 or OX2 receptors; parental control CHO-K1 cells without orexin receptors [1]

At 10 μM, TCS 1102 fully blocked calcium responses to 1 nM orexin-A in both receptor-expressing cell lines in S2 Figure. Yan 7874 responses were only partly sensitive to TCS 1102, and substantial responses also occurred in receptor-negative cells. This supports functional orexin-receptor antagonism under these assay conditions; it does not provide a binding Ki, an antagonist IC50, or a competitive mechanism.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Calcium response to 1 nM orexin-A in CHO-hOX1 and CHO-hOX2 cellsFunctional response inhibition Fully blocked by 10 μM TCS 1102; N = 4; results plotted as % of maximum orexin-A response[1]
Yan 7874-induced calcium responses with and without TCS 1102, compared with receptor-negative CHO cellsResidual calcium signaling Partial inhibition with substantial residual response; N = 6 for Figure 2C–D; mean ± SEM[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM TCS 1102
Exposure duration
30 min pretreatment; 150 s fluorescence recording with 30 s baseline before agonist addition
Method
FLIPR Calcium 4 fluorescence assay at 37°C using FlexStation 3; calcium response measured after orexin-A or Yan 7874 stimulation
Co-treatment
Orexin-A challenge at 1 nM in S2 Figure; Yan 7874 at 18 and 32 μM in S2 Figure and as concentration-response curves in Figure 2C–D
Reported limits
TCS 1102 solvent and final solvent concentration are not specified in the relevant calcium methods/materials. No antagonist concentration-response potency estimate was obtained in this experiment.
Methods and source locations

Compound reported in the paper: TCS 1102; Compound label in the paper: TCS 1102 from Tocris Bioscience

Evidence concerns the reported TCS 1102 reagent in recombinant CHO cells, rather than product-lot equivalence.

Materials and methods: Cell culture and media, Ca2+ elevation, Materials; Results: Ca2+ and phospholipase C; Figure 2C–D and S2 Figure

Calcium response to 1 nM orexin-A in CHO-hOX1 and CHO-hOX2 cells: Fluorescence calcium assay; S2 Figure visually checked. No numerical inhibition percentage inferred from bars. — S2 Figure and caption; Results: Ca2+ and phospholipase C; Materials and methods: Ca2+ elevation

Yan 7874-induced calcium responses with and without TCS 1102, compared with receptor-negative CHO cells: Responses normalized separately to 100 μM ATP for each independent sample; receptor-negative control and subtraction curves shown. — Figure 2C–D and caption; Results: Ca2+ and phospholipase C

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 916141-36-1
Applications Dual orexin receptor antagonist
Formula C27H26N4O2S
Molecular Weight 470.59
SMILES
CN1C2=CC=CC=C2N=C1SCC(=O)N3CCC[C@H]3C(=O)NC4=CC=CC=C4C5=CC=CC=C5

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

TCS 1102 Research References

  1. [1] Orexin receptor agonist Yan 7874 is a weak agonist of orexin/hypocretin receptors and shows orexin receptor-independent cytotoxicity PLoS ONE (2017). PMID: 28575023 DOI: 10.1371/journal.pone.0178526 Source material

Publications

1 publication citing this product

  1. Tung-Yen Lee, .et al. , Front Psychiatry, 2023, Jun 29;14:1196994 PMID: 37457782

Added to your cart

View Cart Checkout
Loading...